Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-TATE-RGD in SSTR2 and Integrin αVβ3 Positive Tumors
NCT06632873Phase 1Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-TATE-RGD in Neuroendocrine Neoplasm (NEN), sponsored by Peking Union Medical College Hospital. Primary endpoint: Standardized Uptake Value. Started Sep 2024; status: recruiting.
02
Drugs
177Lu-TATE-RGD
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT06632873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632873.